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ORIGINAL ARTICLE
Multinutrient supplement containing ephedra and
caffeine causes weight loss and improves metabolic
risk factors in obese women: a randomized controlled
trial
RM Hackman1, PJ Havel1, HJ Schwartz2, JC Rutledge2, MR Watnik3, EM Noceti1, SJ Stohs4,
JS Stern1,2 and CL Keen1,2
1Department of Nutrition, University of California, Davis, CA, USA; 2Department of Internal Medicine, University of
California, Davis, CA, USA; 3Department of Statistics, California State University, East Bay, CA, USA and 4Department of
Pharmacy Science, Creighton University, Omaha, USA
Objective: To determine the safety and efficacy of a dietary supplement with a low dose of ephedra and caffeine in overweight/
obese premenopausal female subjects.
Design: A 9-month, double-blind, randomized control study compared the efficacy and safety of a dietary supplement with
ephedra and caffeine to a control supplement.
Subjects: Sixty-one healthy, premenopausal women with body mass index (BMI) from 27 to 39 kg/m2 were randomly assigned
and received a dietary supplement (40 mg/day ephedra alkaloids, 100 mg/day caffeine, high potency mixture of vitamins,
minerals, omega-3 fatty acids) or a control supplement for 9 months.
Measurements: Efficacy: changes in body weight, body composition, lipids, insulin, leptin, adiponectin, ghrelin, and self-reports
of physical activity, diet and quality of life indices. Safety: blood pressure, heart rate, electrocardiograms, urinalysis, blood
histology, serum chemistry measures and self-reported symptoms.
Results: Forty-one women completed the study. The treatment group lost significantly more body weight (7.18 kg) and body
fat (5.33 kg) than the control group (2.25 and 0.99 kg, respectively), and showed significant declines in heart rate, serum
cholesterol, triglycerides, cholesterol to high-density lipoprotein ratio, glucose, fasting insulin, and leptin. Blood pressure,
electrocardiograms, other clinical chemistry measures, blood histology, urinalysis, and self-reported physical activity were similar
in the groups. Minor symptoms included dry mouth, insomnia, nervousness and palpitations. The treatment group reported
more energy and decreased appetite compared to controls and scored higher on a quality of life domain assessing vitality.
Conclusion: A dietary supplement containing a low potency ephedra/caffeine mixture appeared safe and effective in causing
loss of weight and body fat, and improving several metabolic parameters, including insulin sensitivity and lipid profiles when
tested under physician supervision. Such supplements could be a useful tool to assist with weight loss.
International Journal of Obesity advance online publication, 21 March 2006; doi:10.1038/sj.ijo.0803283
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Introduction
An estimated 64% of American adults are overweight or
obese (body mass index (BMI) in kg/m2X25.0).1 Obesity is
associated with a number of chronic health problems,
contributes to at least 300 000 deaths per year,2 and
conservatively costs an estimated $75 billion annually in
health care and related costs in the US.3
Physicians tend to underreport obesity, and less than half
of obese persons are advised to lose weight or offered a
supervised diet or exercise program by their doctor.4,5 These
trends may encourage people seeking weight loss to respond
to heavily marketed products such as nutrition supplements,
many of which have limited evidence of safety or efficacy.
Studies in the early 1990s found that a combination of
ephedrine and caffeine significantly reduced body weight
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2- and 6-month studies using combinations of ephedra (Ma
Huang) and caffeine reported similar weight loss findings.7,8
The US Food and Drug Administration (FDA) banned the sale
of dietary supplements containing ephedrine alkaloids in
2004, citing concerns such as consumption of high,
unregulated dosages, and use by at-risk populations with
comorbid conditions.9 However, in 2005, a US District Court
found insufficient evidence of adverse events related to the
sale of a dietary supplement containing 10 mg/day ephedra
alkaloids, and ordered the FDA to rewrite its ephedra rule
with consideration for dose–response relationships (Nutra-
ceutical Corp. and Solaray, Inc. vs Lester Crawford, Acting
Commissioner, US FDA et al.).
Intake of vitamins, minerals, and omega-3 fatty acids may
be compromised in overweight and obese individuals due to
improper dietary choices, and a multinutrient supplement
may be valuable in providing basic micronutrient support.
We tested the hypothesis that a high-potency multivitamin
and mineral formula, plus additional omega-3 fatty acids
and botanical extracts including a low level of ephedra
alkaloids and caffeine would have a greater effect in
reducing body weight and body fat than a control formula
containing a lower potency multivitamin and mineral
formula devoid of omega-3 fatty acids, botanical extracts,
ephedra alkaloids, and caffeine over a 9-month period. We
further evaluated the effects of these two types of supple-
ments on cardiovascular and metabolic indices, serum
chemistry, self-reported symptoms, and behavioral and
psychosocial measures.
Methods
Subjects
Sixty-one healthy pre-menopausal women, aged 25–47 years
old, with BMI from 27 to 39 kg/m2 were enrolled in the study
(Table 1). During an enrollment period from February to
August 2002, 216 prospective volunteers responded to
recruitment. Ninety-four passed a telephone-based health
screening and were further evaluated by a health interview,
physical exam, and clinical chemistry. Exclusion criteria
included resting systolic blood pressure greater than
140 mm Hg or diastolic blood pressure greater than
90 mm Hg, history of, or existence of, any medical condition,
use of prescription medications (except birth control pills),
use of antihistamines or other medications used for mild
asthma, coughs, colds, and allergies for 30 days prior to
randomization and for the duration of the study, caffeine
intake greater than 150 mg/day, smoking presently or at least
6 months prior to the study, involvement in any weight
loss program or diet presently or at least 6 months prior
to the study, and women who were pregnant, lactating or
planning a pregnancy during the study period. All subjects
provided written informed consent, and the University of
California, Davis Institutional Review Board approved the
study protocol.
Study design
Randomization of an equal proportion of subjects to one of
two groups was conducted with a random number generator
in multiples of 20.10 Subjects and research staff were blinded
to group assignment throughout the intervention. A sealed
copy of the code was available to the study physicians for
emergency purposes. The statistician was the only person
with access to the code until completion of the study and
data verification.
The control group received a supplement containing
vitamins and minerals at 100% Daily Value, a small amount
of lutein, a corn oil capsule, and a cellulose tablet (Table 2).
The treatment group received a high-potency multivitamin
and mineral formula, an omega-3 fatty acid capsule and a
botanical supplement containing Garcinia cambogia extract,
green tea extract, ephedra (Ephedra sinica) extract, guarana
(Paullinia cupana) extract (a source of caffeine), and other
botanical extracts (Table 2). The treatment group received a
total of 40 mg of ephedra alkaloids per day, provided as
20 mg prior to breakfast and 20 mg prior to lunch, and
100 mg of caffeine per day, provided as 50 mg prior to
breakfast and 50 mg prior to lunch. Independent analysis
conducted at the Department of Pharmacy Science, Creight-
on University, confirmed the ephedrine and caffeine con-
tent. Study supplements were provided in daily strip packs
and were of similar size, shape and color. Subjects were
instructed to take the botanical caplets or placebo 30–45 min
prior to breakfast and again prior to lunch, and to take the
multivitamin-mineral caplets and omega-3 fatty acid or corn
Table 1 Baseline characteristics of the subjectsa
Characteristic Control (N¼ 32) Treatment (N¼29)
Race or ethnic group
African American 1 2
Filipino American 2 0
Latino American 2 6
Mexican American 0 1
Asian 1 1
Polynesian 1 0
Caucasian 24 19
Did not reply 1 0
Age (year) 35.570.9 38.471.1
Body mass indexb 31.670.5 32.470.6
Weight (kg) 84.371.7 88.672.4c
Systolic blood pressure (mm Hg) 10571.4 10771.7
Diastolic blood pressure (mm Hg) 6871.2 7071.3
Heart rate 69.571.5 67.171.4
Cholesterol (mg/dl)
Total 197.476.4 182.475.8
Low-density lipoprotein 124.975.7 113.775.1
High-density lipoprotein 48.571.9 47.272.1
Triglycerides (mg/dl) 105.8711.7 107.8711.0
aPlus-minus values are means7s.e.m. bBody mass index is the weight in
kilograms divided by the square of the height in meters. cA significant
difference (Po0.05) in body weight existed between the two groups after
randomization at baseline.
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oil capsule with either lunch or dinner. Compliance was
assessed at each clinic visit and by scheduled telephone
interviews weekly, then monthly.
Women were instructed to refrain from eating or drinking
beverages containing caffeine or alcohol for at least 12 h, and
to refrain from heavy physical activity for 3 h, prior to the
clinic visits. Normal hydration was maintained during the
testing. Body weight was measured to the nearest 0.1 kg
while wearing light clothing and without shoes using an
electronic scale (Scale-Tronix 6002). Height was measured to
the nearest 0.5 cm without shoes using a wall-mounted
stadiometer (Ayrton S100). Body composition was assessed
with a Xitron Hydra 4200 bioelectrical impedance spectro-
meter (Xitron Technologies, San Diego, CA, USA) in a supine
position 30 min after voiding.11 The manufacturer’s software
was used to calculate body composition. Body weight and
body composition were measured at baseline and at months
1.5, 3, 6, and 9 after beginning the supplement regimens.
With the subject remaining supine after measurement of
body composition, a 12-lead resting electrocardiograph
(ECG) (Welch Allyn) was recorded and subsequently read
by a board-certified cardiologist (JCR). Electrocardiograph’s
were recorded at baseline, weeks 1, 2, and 4, and at months
1.5, 3, 6, and 9.
Blood pressure was measured three times in a resting,
seated position with an aneroid sphygmomanometer (Welch
Allyn), according to standardized methods.12 A 1-min rest
period was observed between each measurement. The last
two readings were averaged for the final measurement.
Heart rate was measured in beats per minute after the second
blood pressure reading. Blood pressure and heart rates
were recorded at baseline, weeks 1, 2, and 4, and monthly
thereafter. Accepted values for normal blood pressure at the
time of the study (130/85 mm Hg) were used.13
Blood collected from the antecubital vein and urine
samples were obtained at baseline and at months 1.5, 3, 6,
and 9. Serum levels of sodium, potassium, bicarbonate,
chloride, magnesium, carbon dioxide, urea nitrogen, creati-
nine, glucose, phosphorus, calcium, protein, albumin, alka-
line phosphatase, aspartate transaminase (AST/SGOT), total
bilirubin, alanine transaminase (ALT/SGPT), creatinine
kinase, lactate dehydrogenase, ketone bodies, cholesterol,
high-density lipoprotein (HDL) cholesterol, and triglycerides
were determined by chemistry analyzers (Beckman LXI
and LX20 Pro). Low-density lipoprotein (LDL) cholesterol
was calculated (TChol–HDL–TG/5¼Calculated LDL). Insulin,
thyroxine, and thyroid stimulating hormone were assessed
by chemiluminescent immunoassay (Bayer Advia Centaur).
The above tests, as well as blood histology, were performed
by the Department of Pathology at the University of
California Davis Medical Center. Urinalyses by dipstick and
urine pregnancy tests were performed at our clinic.
Plasma glucose concentrations were measured with a
YSI Glucose Analyzer Model STAT 2300 (Yellow Springs
Instruments, Yellow Springs, OH, USA). Free fatty acids
were assayed with an enzymatic colorimetric assay (Wako
Table 2 Composition of supplements for control and treatment groups
Ingredient U/day DRI Amount
Control Treatment
Vitamin A (palmitate)a mg 700 1200 750
Vitamin A (beta-carotene)a mg 700 300 3750
Vitamin C mg 75 60 1200
Vitamin Db mg 5 10 10
Vitamin Ec mg 15 13.5 70.5
Vitamin K mg 90 25 0
Thiamin mg 1.1 1.5 9
Riboflavin mg 1.1 1.7 10.2
Niacind mg 14 20 160
Vitamin B6 mg 1.3 2 16
Folatee mg 400 400 800
Vitamin B12 mg 2.4 6 36
Biotin mg 30 30 100
Pantothenic Acid mg 5 10 40
Calcium mg 1000 162 150
Iron mg 18 18 0
Phosphorus mg 700 109 100
Iodine mg 150 150 0
Magnesium mg 320 100 200
Zinc mg 8 15 15
Selenium mg 55 20 80
Copper mg 900 2000 2000
Manganese mg 1.8 2 4
Chromium mg 25 120 200
Molybdenum mg 45 75 50
Chloride mg f 72 0
Potassium mg f 80 300
Boron mg f 150 300
Nickel mg f 5 0
Silicon mg f 2 500
Tin mg f 10 0
Vanadium mg f 10 50
Lutein mg f 250 0
Eicosapentaenoic acid mg 0 0 180
Docosahexaenoic acid mg 0 0 120
Choline mg 0 0 60
Coenzyme Q-10 mg 0 0 150
Garlic extract mg 0 0 50
L-Glutathione mg 0 0 5
L-Methionine mg 0 0 100
Bioflavonoids mg 0 0 100
L-Carnitine mg 0 0 25
Taurine mg f 0 50
Beta-sitosterol mg f 0 25
Gingko biloba extract mg f 0 10
Silymarin extract mg f 0 5
Red wine polyphenols mg f 0 5
Garcinia cambogia extract mg f 0 2000
Tulsi extract mg f 0 50
Gymnema sylvestre extract mg f 0 10
Green tea extract mg f 0 20
Oolong tea extract mg f 0 200
Eleutherococcus senticosis extract mg f 0 50
Guarana extract mg f 0 550g
Ephedra extract mg f 0 500h
aAs retinol activity equivalents. bAs cholecalciferol. cAs alpha-tocopherol. dAs
niacin equivalents. eAs dietary folate equivalents. fNo DRI established.
gContains 100 mg caffeine. hContains 40 mg ephedrine group alkaloids.
Multinutrient supplement with low-dose ephedra and caffeine
RM Hackman et al
3
International Journal of Obesity
Chemicals USA, Richmond, VA, USA) adapted to a microtiter
plate reader. Intra- and interassay coefficients of variation in our
laboratory are 4.7 and 7.5%, respectively. Insulin was assayed
as described elsewhere,14 using human insulin standards
(Linco Research, St Charles, MO, USA), (3-125I) insulin
(human recombinant) (Amersham Biosciences, Piscataway,
NJ, USA) and antiinsulin antisera (Radioassay Systems
Laboratories, Carson, CA, USA). Intra- and interassay varia-
tions are 5.5 and 8.9%, respectively. Leptin was measured
with a radioimmunoassay kit using an I-125-iodinated
human leptin tracer and human leptin standards (Linco
Research, St Charles, MO, USA). Intra- and interassay
variations are 5.8 and 5.7%, respectively. Adiponectin was
determined with a radioimmunoassay kit using an I-125-
iodinated murine adiponectin tracer, a multispecies adipo-
nectin rabbit antiserum, and human adiponectin standards
(Linco Research, St Charles, MO, USA). Intra- and interassay
variations are 5.1 and 8.6%, respectively. Ghrelin was
measured with a radioimmunoassay kit using rabbit anti-
serum specific for the synthetic peptide (Phoenix Pharma-
ceuticals, Belmont, CA, USA). Intra- and interassay variations
are 5.9 and 13.3%, respectively. The homeostasis assessment
model (HOMA-IR) was used to calculate an index of insulin
resistance/sensitivity.15
Self-reported symptoms were assessed in person at base-
line, weeks 1, 2, and 4 and monthly hereafter, as well as by
regularly scheduled telephone calls. Events were self-rated
for intensity (mild, moderate, severe, or serious), reviewed
by the study physicians and classified according to the
FDA coding system and thesaurus for adverse events
terminology.16
Food intake was assessed by a standardized self-adminis-
tered food frequency questionnaire (Block Food Frequency
Questionnaire17) at baseline and month 9. Physical activity
was assessed by an interview-administered standardized
instrument (Seven-Day Physical Activity Recall18) at baseline
and at months 1.5, 3, 6, and 9. Psychosocial indices were
determined at baseline and months 1.5, 3, 6, and 9 using a
self-administered, standardized survey (Medical Outcomes
Study 36-item Health Survey [SF-36 version 2]19) to assess
domains of general health status, limitations in physical
activities due to health problems, limitations in usual role
activities due to physical or emotional problems, bodily
pain, energy and fatigue levels, social functioning, general
mental health and general health perception.
Statistical analysis
Outcome measures were analyzed using mixed model
analysis of variance. Least squares means comparisons were
performed to determine significant differences between
groups overall and between the groups at specific time
points. When model assumptions were not met, transforma-
tions were used prior to analysis.20 Missing values were not
imputed; they were left as missing.21,22 Fisher’s exact test was
used to determine differences between groups for categorical
response terms (e.g. blood pressure above normal values).
Reported P-values were two-sided and a P-value of 0.05 or
less was considered statistically significant. Analyses were
performed with SAS software (version 9.1).23
Results
Attrition
Of the 61 subjects enrolled, 41 (67%) completed the 9-
month study. Figure 1 depicts the randomization flow and
reasons for attrition. The study code never needed to be
broken for emergency purposes. No subjects were removed
from the study due to clinically abnormal changes in serum
chemistry, hematology, urinalysis, pregnancy, or ECG read-
ings. No subjects were removed by the study physicians due
to severe or serious symptoms. Of the nine subjects in the
treatment group who withdrew, two started a medication
that was exclusionary for the study, two reported headaches,
one was lost to follow-up, one was noncompliant and one
each reported insomnia, nervousness, and dizziness. Of the
nine subjects in the control group who withdrew, four were
lost to follow-up, three reported personal conflicts, one
refused to participate, and one started a medication that was
contraindicated for study participation.
Body weight and composition
The treatment group had a slightly higher average body
weight (89.0 kg) than the control group (84.0 kg) at baseline.
Body weights were rank transformed prior to statistical
analysis, and all values from subjects completing 3 months
of the intervention were included in the model. Significant
differences between groups for weight loss occurred at
months 1.5, 3, 6, and 9 (Po0.0001 between groups at each
time; Figure 2), with the treatment group losing significantly
more body weight than the control group (overall change
between groups, P¼0.0022). Changes in BMI were similar to
those found for changes in body weight, with the treatment
group showing a significant reduction in BMI at months 1.5,
3, 6, and 9 compared to controls (Po0.0001 between groups
at each time; P¼0.0002 overall). The amount of body fat did
not differ between groups at baseline (P¼0.71). Significant
reductions in body fat were noted for the treatment group
at months 1.5, 3, 6, and 9 compared to controls at each
time, and was significant overall (P¼0.0017; Figure 2). No
differences in fat-free mass were found between the two
groups at specific visits (P¼0.60).
Blood pressure, heart rate, and electrocardiograph
Mean systolic and diastolic blood pressure values remained
fairly constant throughout the intervention and were within
the normal range at all measurement periods. At the time of
the study, normal blood pressure was defined as systolic
o140 mm Hg and diastolico90 mm Hg. Using these criteria,
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no differences in the number of high values for systolic or
diastolic blood pressure were found between groups. By the
completion of the study, new standards had been adopted to
define normal blood pressure as systolic o120 mm Hg and
diastolic o80 mm Hg. Using these newer criteria, no differ-
ences in systolic blood pressure were observed between
groups except at month 3. No differences in diastolic values
were found (Table 3).
Heart rates were similar between groups at baseline and
were log transformed for analysis. Following ANOVA, mean
values and 95% confidence intervals were calculated24 and
are shown in Table 3. Heart rates in the control group
were significantly higher at week 1, month 3, and month 9
compared to the treatment group. Heart rates for the
treatment group were significantly higher at week 2 than
the control group. Overall, the treatment group showed a
significant decline in heart rate compared to the control
group (P¼0.0003).
Most electrocardiograms (ECGs) were considered within
the normal range. Clinically insignificant deviations in ECGs
were noted for a small number of subjects in each group
at various times, but in no case were the readings suffi-
ciently alarming to warrant discontinuation of any subject.
One subject in the treatment group was found to have a
heart murmur, confirmed by an echocardiogram, which was
diagnosed by the study cardiologist during the blinded phase
of the intervention. The murmur most likely was due to a
congenital anomaly and was not considered to be clinically
significant.
Serum lipids, chemistry, urinalysis, and histology
Total serum cholesterol levels were significantly higher in
the control group at baseline than in the treatment group
(P¼0.002). Both groups showed a similar decline in
cholesterol over the course of the study (P¼0.78; Table 4).
High-density lipoprotein cholesterol was similar at baseline
for the two groups (P¼0.49) and was log transformed for
analysis.24 Levels did not differ between groups at any time
except month 6, when the treatment group had significantly
217 Assessed for Eligibility 
  61 Randomized 
94 Medically Screened
123 Excluded 
86 Not Meeting Inclusion Criteria  
 37 Refused to Participate 
33 Excluded 
 33 Not Meeting Inclusion Criteria  
29 Assigned to 
Treatment Group 
26 at 6 weeks 
31 Assigned to 
Control Group
29 at 6 weeks 
22 at 12 weeks 23 at 12 weeks 
20 at 24 weeks 23 at 24 weeks 
19 at 36 weeks 23 at 36 weeks
3 Excluded 
1 Non-compliance 
1 Insomnia 
1 Nervousness
4 Excluded 
1 Lost to Follow-up 
1 Dizziness 
1 Headaches 
1 Medication 
2 Excluded 
1 Medication 
1 Headaches 
1 Excluded 
1 Surgery 
2 Lost to Follow-up 
6 Excluded 
2 Lost to Follow-up 
3 Personal Conflict 
1 Medication 
1 Excluded 
1 Refused to Participate 
Figure 1 Randomization flow.
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higher HDL than the control group (Po0.0001). The ratio of
total cholesterol to HDL cholesterol was significantly lower
at months 1.5, 3, 6, and 9 for the treatment group compared
to the control group, as was the trend over time (P¼0.004).
Low-density lipoprotein cholesterol was significantly higher
at baseline in the control group compared to the treatment
group, and both groups showed a decline over the course of
the intervention. Triglyceride values were log transformed
for analysis. Values for the treatment group consistently
declined over the study, while values in the control group
increased from baseline to 6 months and then declined at 9
months. Differences between groups were significant over
time (P¼0.050).
Among all other clinical chemistry, blood histology and
urinalysis values monitored, no clinically significant changes
were found.
Endocrine parameters
Fasting glucose levels were unchanged in the control group
over time, while values in the treatment group declined
significantly (P¼0.001) (Table 5). Fasting plasma insulin
concentrations were not different after 9 months in control
subjects but decreased by nearly 18% (P¼0.017) after 9
months in the treatment group. Insulin sensitivity as
assessed by the HOMA index was unchanged in the control
group, but improved by 23% (P¼0.004) in the group
consuming the dietary supplement with ephedra and
caffeine. The absolute and proportional (percent) changes
of plasma glucose, insulin, and insulin sensitivity in the
treatment group were not related to either the absolute or
the percent change of body fat mass by simple regression
analysis. Baseline plasma leptin concentrations averaged
approximately 20–22 ng/ml in both groups. Leptin was
unchanged in the control group, but decreased by
25.875.2% (P¼0.0004) after 9 months in the supplement-
treated subjects (Table 5). The absolute and proportional
changes of leptin were significantly correlated with the
absolute and percent changes of BMI (P¼0.0005 and 0.001,
respectively). Circulating adiponectin levels at baseline were
similar in the control and treatment groups and remained
unchanged after 9 months. Initial concentrations of total
plasma ghrelin averaged approximately 700 pg/ml in both
the control and supplement-treated groups, and were un-
changed after 9 months in both groups.
Diet, physical activity, and quality of life
At the beginning of the study, reported daily energy intake
for the treatment group was 8079 kJ (1930 kcal) compared to
6614 kJ (1580 kcal) for the control group (P¼0.005). After 9
months, the reported mean daily energy intake in the
treatment group decreased to 6367 kJ (1521 kcal) (Po0.006
compared to baseline value), while the mean daily caloric
intake in the control group was 6455 kJ (1542 kcal). Two
subjects reported energy intake o2512 kJ/day (o600 kcal/
day) at both the beginning and end of the study, and six
additional subjects reported energy intakes of o4186 kJ/day
(o1,000 kcal/day).
The two groups reported similar levels of physical
activity at the beginning and end of the study, and no
differences were found between groups. Six of the seven
quality of life domains assessed did not differ between
groups. Subjects in the treatment group reported a
significantly lower vitality index at baseline compared to
those in the control group, and the vitality scores rose
significantly for the treatment group while no change was
found in the control group.
Self-reported symptoms
The treatment group reported significantly more dry mouth,
nervousness, and palpitations than the control group
(Table 6). None of the symptoms were severe and no subject
was dropped from the study due to such self-reports. The
treatment group also reported significantly more increased
energy and decreased appetite than the control group.
Change in Body Weight (kg)
-8
-7
-6
-5
-4
-3
-2
-1
0
1
Ch
an
ge
 in
 w
ei
gh
t (k
g)
Control
Treatment
Control 0.02 -0.98 -1.67 -2.25
Treatment -0.68 -3.04 -6.31 -7.18
1.5 mo 3 mo 6 mo 9 mo
*
*
*
*
Change in Fat (kg)
-6
-5
-4
-3
-2
-1
0
1
2
Ch
an
ge
 in
 fa
t (k
g)
Control
Treatment
Control 0.8 1.42 -0.35 -0.99
Treatment -0.22 -1.58 -5.34 -5.33
1.5 mo 3 mo 6 mo 9 mo
++
+
++
+++
Figure 2 Changes in body weight and body fat in control and treatment
groups.
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Discussion
Concerns have been appropriately raised about negative side
effects that might be associated with the inappropriate use
of ephedra and caffeine.25–28 While the level of ephedra
alkaloids (40 mg/day) used in the current study was appre-
ciably less than that in other ephedra–caffeine trials of 3- to
6-month duration, the extent of weight loss and change in
body composition in the present study is similar to outcomes
at higher doses.7,8,29,30
A limitation of the study is that the two supplements
differed in concentration of vitamins, minerals, omega-3
Table 3 Blood pressure and heart rate in control and treatment groups
Blood pressure (mm Hg) Control Treatment
n mean 7s.e.m. n mean 7s.e.m. P
Systolic
Baseline 30 105 1.5 29 107 1.7 0.226
Week 1 31 108 1.4 29 108 1.3 0.767
Week 2 30 106 1.5 28 108 1.3 0.252
Week 4 30 108 1.5 28 110 1.5 0.112
Week 6 29 106 3.5 26 107 2.0 0.589
Month 2 26 108 1.4 24 111 2.0 0.113
Month 3 23 107 2.1 22 111 2.1 0.035
Month 4 23 110 1.7 21 111 2.4 0.645
Month 5 23 109 2.7 20 112 2.7 0.350
Month 6 23 110 2.3 19 110 1.6 0.774
Month 7 23 110 1.3 19 112 2.8 0.770
Month 8 23 111 1.9 18 111 2.8 0.814
Month 9 23 112 2.1 17 109 2.2 .075
Overall: Group P¼ 0.609
GroupVisit P¼0.381
Diastolic Baseline 30 68 1.3 29 70 1.3 0.079
Week 1 31 68 1.3 29 69 1.3 0.309
Week 2 30 68 0.9 28 68 1.1 0.978
Week 4 30 68 1.5 28 68 1.3 0.845
Week 6 29 68 1.5 26 69 1.4 0.322
Month 2 26 68 1.4 24 70 1.4 0.195
Month 3 23 68 1.5 22 70 1.7 0.139
Month 4 23 69 1.3 21 71 1.3 0.375
Month 5 23 68 1.5 20 72 1.8 0.065
Month 6 23 69 1.5 19 69 1.4 0.510
Month 7 23 68 1.3 19 71 1.6 0.074
Month 8 23 70 1.0 18 69 1.7 0.408
Month 9 23 70 1.5 17 71 1.9 0.689
Overall: Group P¼ 0.518
Overall: GroupVisit P¼ 0.471
Heart ratea (beats/min) Control Treatment
n Mean Lower 95% CI Upper 95% CI n Mean Lower 95% CI Upper 95% CI P
Baseline 30 68.9 66.7 71.3 29 66.7 64.5 69.0 0.174
Week 1 31 76.9 74.5 79.5 29 72.7 70.3 75.2 0.018
Week 2 30 74.2 71.7 76.7 29 78.6 76.0 81.3 0.016
Week 4 30 75.3 72.8 77.8 28 76.5 73.9 79.2 0.490
Week 6 29 72.3 69.9 74.8 26 70.7 68.2 73.3 0.351
Month 2 26 76.0 73.3 78.8 24 75.6 72.8 78.5 0.818
Month 3 23 72.2 69.5 75.1 22 66.3 63.7 69.0 0.002
Month 4 23 73.9 71.0 76.8 21 74.2 71.3 77.3 0.914
Month 5 23 74.7 71.8 77.6 19 73.7 70.6 76.9 0.600
Month 6 23 71.4 68.6 74.2 19 70.4 67.4 73.5 0.585
Month 7 23 75.3 72.4 78.3 19 77.9 74.6 81.3 0.275
Month 8 23 74.3 71.5 77.3 18 76.3 73.1 79.6 0.402
Month 9 23 75.0 72.2 78.0 17 68.0 65.2 70.9 o.001
Overall: Group P¼ 0.552
Overall: GroupVisit Po0.001.
aMeasurements were log transformed for ANOVA; s.e.m. is not accurate. Means and 95% confidence intervals (CI) were back-transformed.
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Table 4 Mean serum lipid and glucose levels in control and treatment groups
Cholesterol (mg/dl)
Control Treatment
n mean 7s.e.m. n mean 7s.e.m. P
Baseline 30 197 6.6 29 182 5.8 0.002
Month 1.5 28 185 6.8 25 177 5.6 0.009
Month 3 23 190 8.1 22 175 6.8 o0.001
Month 6 23 185 7.1 18 175 5.9 0.017
Month 9 21 184 7.9 19 174 7.1 0.003
Overall: Group P¼ 0.051
GroupVisit P¼0.782
HDL cholesterol a (mg/dl)
Control Treatment
n mean Lower 95% CI Upper 95% CI n mean Lower 95% CI Upper 95% CI P
Baseline 30 46.9 45.0 48.9 29 46.0 44.1 47.9 0.491
Month 1.5 28 44.8 42.9 46.8 25 47.5 45.3 49.9 0.070
Month 3 23 43.3 41.2 45.6 22 44.4 42.1 46.7 0.520
Month 6 23 42.3 40.2 44.5 18 50.7 47.8 53.7 o0.001
Month 9 21 44.7 42.4 47.2 19 47.0 44.5 49.8 0.191
Overall: Group P¼ 0.311
GroupVisit P¼0.002
LDL cholesterol (mg/dl)
Control Treatment
n mean 7s.e.m. n mean 7s.e.m. P
Baseline 30 124.9 5.9 27 113.7 5.3 0.015
Month 1.5 28 118.2 5.2 25 106.7 5.2 0.001
Month 3 23 123.8 6.5 22 108.0 5.6 o0.001
Month 6 23 119.0 6.3 18 104.1 4.4 0.005
Month 9 21 118.0 6.7 19 107.3 5.9 0.004
Overall: Group P¼ 0.032
GroupVisit P¼0.787
Triglyceridesa (mg/dl)
Control Treatment
n Mean Lower 95% CI* Upper 95% CI* n mean Lower 95% CI* Upper 95% CI* P
Baseline 30 91.7 83.5 100.7 29 93.3 84.9 102.6 0.791
Month 1.5 28 92.6 83.8 102.4 25 93.6 84.0 104.2 0.890
Month 3 23 101.1 90.1 113.3 22 83.3 74.1 93.7 0.020
Month 6 23 100.4 89.6 112.6 18 77.3 67.8 88.1 0.003
Month 9 21 82.9 73.5 93.5 19 74.1 65.3 84.3 0.205
Overall: Group P¼ 0.351
GroupVisit P¼0.050
Cholesterol to HDL ratio
Control Treatment
n mean 7s.e.m. n mean 7s.e.m. P
Baseline 30 4.17 0.14 29 4.07 0.23 0.368
Month 1.5 28 4.19 0.16 25 3.77 0.22 0.001
Month 3 23 4.40 0.18 22 3.80 0.22 0.001
Month 6 23 4.40 0.17 18 3.23 0.14 o0.001
Month 9 20 4.26 0.19 19 3.57 0.22 o0.001
Overall: Group P¼ 0.018
GroupVisit P¼0.001
aMeasurements were log transformed for ANOVA; s.e.m. is not accurate. Means and 95% confidence intervals (CI) were back-transformed.
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fatty acids, and some botanical extracts. The multicompo-
nent dietary supplement with ephedra and caffeine does
not enable assessment of the efficacy or safety of individual
ingredients. Mixed ingredient formulas containing ephedra
and caffeine are typically studied in clinical trials.7,8,27–30 A
broad based multinutrient supplement mixture containing
vitamins and minerals may be useful for weight loss for a
number of reasons. Insufficient intake of numerous vitamins
and minerals has been linked to a number of chronic
diseases.31 Low levels of plasma vitamins C and E and serum
levels of zinc and magnesium have been associated with
a higher percent body fat,32 and low plasma zinc levels
have been associated with higher leptin production in obese
humans.33 Botanical extracts in addition to ephedra may be
useful for weight loss. Extracts of Garcinia cambogia contain
()-hydroxycitric acid (HCA), which have been reported
to decrease energy intake by 15–30% in overweight human
male and female subjects consuming 900 mg/day HCA.34
Hydroxycitric acid has also been shown to promote fat
oxidation and reduce the rate of weight gain in male and
female rats.35
Self-reported symptoms were minor and transitory among
the subjects who completed the study, and none were
terminated from participation due to any clinically signifi-
cant measurement. The higher incidence of dry mouth and
insomnia reported here are consistent with other studies.6,8
The treatment group reported more nervousness and
palpitations than the control group. The incidence of
dizziness and headache were approximately similar between
groups. Reports of decreased appetite and increased energy
found here have not been noted in other studies.
The present study found no differences in blood pressure
or ECG between treatment and control groups. Mean blood
pressure values were within the normal range at each
measurement period for both groups. Although subjects in
the treatment group lost weight, blood pressures remained
unchanged, a finding consistent with other ephedra–caffeine
studies that enrolled overweight and obese subjects with
normal blood pressure.7,30 In contrast, acute hemodynamic
and ECG studies with a single dose of Metabolife 356, a
dietary supplement with ephedra and caffeine (12 mg
ephedra alkaloids, 40 mg caffeine, and 16 other ingredients),
reported increases in systolic blood pressure and the mean
maximal QTc interval.27 Differences in ECG results between
the two studies may be due to a number of reasons,
including different ingredients in the supplements that were
tested, different ECG measurement techniques, differences
in the physiology or metabolism of subjects tested, or
random chance. Differences in experimental design (single
dose vs multiple dosing with possible adaptation effects)
may also be important to consider.
The decreases in total and LDL cholesterol and triglyceride
levels indicate that these risk factors for atherosclerosis and
other cardiovascular morbidity/mortality are improved in
conjunction with the weight loss induced by the treatment.
Similarly, the decreases in fasting glucose, insulin, and the
HOMA-IR index observed after weight loss in the treatment
group indicate that insulin sensitivity was improved, an
effect that would be expected to decrease the risks of
impaired glucose intolerance, metabolic syndrome, and
type-2 diabetes associated with obesity.
The decrease in plasma leptin (B25%) at 9 months that
accompanied the decrease of total body fat (B18%) has
been observed during both acute energy restriction and in
Table 5 Endocrine parameters in control and treatment groups
Control Treatment P-value vs
control
Mean7s.e.m. P-value vs
baseline
Mean7s.e.m. P-value vs
baseline
Fasting glucose (mg/dl)
Baseline 85.571.4 86.371.3
9 Month 83.671.7 79.571.6
D9 Month 2.271.5 0.149 6.871.7 0.001 0.033
Fasting insulin (mU/ml)
Baseline 12.370.9 14.571.3
9 Month 13.371.9 12.071.6
D9 Month 0.971.2 0.960** 2.671.0 0.017 0.023*
HOMA-IR
Baseline 47.173.9 55.574.8
9 Month 51.078.1 42.675.7
D9 Month 3.275.1 0.687** 13.074.0 0.004* 0.011*
Leptin (ng/ml)
Baseline 20.771.7 22.671.5
9 Month 19.672.4 17.071.8
D9 Month 1.471.5 0.362 5.671.3 0.0004 0.027
Adiponectin (mg/ml)
Baseline 8.770.7 9.570.9
9 Month 9.470.9 9.971.0
D9 Month 0.870.4 0.091 0.570.5 0.376 0.672
Ghrelin (pg/ml)
Baseline 752.1748.1 694.9752.6
9 Month 758.0749.8 744.4771.0
D9 Month 5.9720.4 0.774 49.5731.8 0.137 0.243
*The overall ANOVA model was not significant but the pre-post changes were
significant. **Uses sign-rank test.
Table 6 Number of most commonly self-reported symptoms in control and
treatment groups
Condition Control Treatment
Appetite decreased 1 22
Dizziness 3 5
Dry mouth 4 14
Energy increased 3 19
Fatigue 4 7
Headache 13 16
Insomnia 2 7
Nausea 3 7
Nervousness 1 13
Palpitations 1 13
Multinutrient supplement with low-dose ephedra and caffeine
RM Hackman et al
9
International Journal of Obesity
response to weight/body fat loss.36 A reduction in leptin after
weight loss has been associated with increased appetite37 and
decreased energy expenditure,38 and may be a predisposing
factor to weight regain when weight loss treatment is
discontinued.39 However, results from the present study
showed maintenance of weight loss between 6 and 9
months.
Circulating levels of the orexigenic gastric hormone
ghrelin did not increase after weight loss in the treatment
group, in contrast to increases of ghrelin reported in other
studies when subjects lose weight following energy-restricted
diets.40 The lack of an increase of ghrelin after weight loss in
the supplement-treated group could contribute to decreased
appetite and maintenance of weight loss with the supple-
ment combination. Further studies are needed to determine
the mechanism underlying the failure of ghrelin to increase
during weight loss induced by this regimen. Circulating
adiponectin concentrations did not increase after the
moderate degree of weight loss induced by the supplement
treatment. Increases of adiponectin are observed after greater
degrees of weight loss, such as after gastric bypass surgery
and are associated with improved insulin sensitivity.41 Levels
of adiponectin in the treated subjects were not associated
with the decreases of fasting insulin levels or HOMA-IR
indicating that changes of adiponectin are unlikely to have a
role in the observed improvement of insulin sensitivity.
Subjects were instructed to follow their normal dietary
intakes and did not receive standardized dietary advice. The
significant decrease in reported energy intake in the treat-
ment group, but not in the control group, may account in
part for the differences in weight loss, particularly since
reported levels of physical activity did not change in either
group. However, indirect methods of assessing food intake
have limitations and accuracy is difficult to verify. It is likely
that both a reduction in food intake and an increase in
thermogenesis are responsible for the significant weight and
fat loss found in the treatment group.
Improved vitality found in the treatment group has also
been associated with weight loss among women in the
Nurses’ Health Study.42 In addition to weight loss, the
improved vitality reported here might be associated with an
increased perception of energy, which may be due to the
intake of ephedrine and caffeine, and/or supplementation
with vitamins, minerals or omega-3 fatty acids.
Adaptation effects from the long-term intake of ephedra
and caffeine in combination with vitamins, minerals, and
omega-3 fatty acids may also explain the differences in
metabolic and hemodynamic effects noted here compared
with results from acute studies. Tachyphylaxis and physio-
logical adaptation, resulting in decreased side effects over
time, have been reported in studies using a combination of
ephedrine, caffeine and aspirin.43,44 In the present study, no
differences were found in blood pressure or ECG measure-
ments between the two groups, in contrast to abnormalities
in ECG and blood pressure noted after a single dose of
Metabolife.27 Further, a study of 16 healthy adults taking two
doses, 5 h apart, of an ephedra–caffeine mixture (total intake
23 mg ephedra alkaloids, and 167 mg caffeine) or of a
commercial product, Xenadrine RFA (25 and 185 mg,
respectively) found increases in blood pressure and heart
rate compared to a placebo treatment when measured over a
17-h period.45 The study also reported significant increases
in blood glucose and insulin levels over a 10-h period when
ephedra–caffeine or the commercial product was taken,
compared to levels when taking a placebo. In contrast, our
study did not find changes in blood pressure, but did find
significant decreases in heart rate, blood glucose, fasting
insulin, and insulin sensitivity in the treatment group
compared to controls. Another possibility to explain these
differences is the presentation of ephedra alkaloids and
caffeine as part of a multinutrient system, compared to
isolated herbal extracts or herbal combinations devoid of
vitamins, minerals, and omega-3 fatty acids.
Toxicity studies in mice fed up to 10 times the same
dietary supplement used in the present study found no
significant changes in normal serum chemistry, including
cardiosensitive enzymes (creatine kinase, lactate dehydro-
genase, and aspartate aminotransferase) and normal cardiac
histopathological architecture.46 The normal serum chem-
istry results in mice over a wide range of intake are consistent
with the clinical findings reported here.
While lifestyle choices are necessary for weight loss, a
variety of treatment interventions must be available to
physicians as part of a comprehensive approach. Mean
weight loss in the group of women taking the dietary
supplement with ephedra and caffeine in this study is similar
to mean weight loss found in a meta-analysis of obese
patients treated with orlistat in addition to a hypocaloric
diet.47 Under the conditions tested (carefully selected,
healthy overweight and obese population; physician pre-
scription and monitoring; regular checks of blood pressure,
heart rate, ECG, and self-reported symptoms), a low-dose of
ephedra alkaloids and caffeine combined with a broad-
spectrum multinutrient supplement and other botanical
extracts may be a useful option to help physicians and
patients with safe and effective weight loss. Results from the
present study cannot be generalized to other population
groups that may be at elevated risk, such as those with
high blood pressure, diabetes, or a family history of heart
disease. Patients with contraindicated conditions may not
be appropriate for this regimen. Given the limited number
of clinical options available for obesity treatment, further
studies of low-dose ephedra and caffeine mixtures in
conjunction with dietary supplements under regulated
conditions may provide physicians with additional safe
and effective therapies.
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LETTER TO THE EDITOR
Response to Dr Inchiosa
International Journal of Obesity (2007) 31, 1482–1483;
doi:10.1038/sj.ijo.0803627; published online 17 April 2007
Our opportunity to respond to the letter by Inchiosa allows
us to expand upon and update a number of important points
that were not fully addressed in our paper ‘Multinutrient
supplement containing ephedra and caffeine causes weight
loss and improves metabolic risk factors in obese women: a
randomized controlled trial’.1 Inchiosa correctly points out
that our study tested the effect of a high-potency mixture of
vitamins, minerals, omega-3 fatty acids and botanical
extracts including ephedra and caffeine, against a control
formula containing 100% of the Daily Value of vitamins and
minerals. This is indeed a controlled study design that has
been used in numerous other studies assessing ephedra and
caffeine, and our title, introduction and conclusions very
carefully note the multinutrient formula that was tested,
rather than drawing conclusions regarding only the effects of
ephedra and caffeine.
We believe that it is unlikely that a Garcinia cambogia
extract containing ()-hydroxycitric acid (HCA) could have
accounted for approximately 60% of the weight loss noted in
our results. While a few studies suggest that HCA can reduce
food intake or promote weight loss,2 a number of other stu-
dies have produced negative results.3–5 One of us (PJH) has
recently completed a double-blind, placebo-controlled study
in overweight/obese men and women, administering HCA
(2700 mg/day) plus chromium polynicotinate (400 mg/day)
for 12 weeks. No differences were measured in appetite,
energy intake, body weight or body composition (personal
communication), suggesting a minimal contribution of
HCA, if any, to the body weight and body fat loss reported
in the current study.
It is correctly noted that the treatment group had a
significantly higher baseline body weight than the control
group, although all participants were randomly assigned at
the inception of the study in a double-blind manner. We do
not think this initial difference accounts for the substantial
differences in body weight and body fat loss noted at the end
of the study. While differences in the reported daily energy
intake at baseline between the two groups are duly noted,
one must be skeptical of self-reported diet records, which
give at best a rough estimate of a person’s true energy intake.
Indeed, we note that numerous self reports from our
participants showed an unusually low estimation of energy
intake (twoo2512 kJ/day (o600 kcal/day) and sixo4186 kJ/
day (o1000 kcal/day)), which raises doubt regarding the
accuracy of the baseline energy intake measurements.
The issue of palpitations was considered very carefully by
the study physicians and authors. Self-reported symptoms
from all participants were noted and graded by one of us
(HJS) as mild, moderate or severe. All reports of palpitations
were minor, and none of them persisted more than a few
days. At no point was any participant removed from the
study as a result of these symptoms. Electrocardiograms were
obtained regularly on all participants, read (blindly) by one
of us (JCR; a board-certified cardiologist) and none of the
readings showed any patterns that caused concern. Palpita-
tions are a well-known side effect of ephedra and caffeine,
but at the doses used in our study, they seemed to subside
and disappear after a brief period. Our observation is
consistent with tachyphylaxis of this effect and with other
studies on ephedrine/ephedra and caffeine previously pub-
lished in this journal.6,7
Statements about the legal and regulatory status of dietary
supplements containing ephedra and caffeine contained in
our paper were accurate in March 2006, at the time of its
online publication. Subsequent to the online publication, on
17 August 2006, the Tenth US Circuit Court of Appeals
upheld the FDA’s position that unregulated sale of supple-
ments containing ephedra and caffeine posed a public health
risk. Most recently, a petition was filed asking the US
Supreme Court to review the Tenth Circuit Court of Appeals
ruling on 3 January 2007,8 thus this is still an evolving issue.
Regardless of the next legal decision, it is important to note
that the FDA’s decision was based on unregulated use that
enabled anyone to freely obtain ephedra and caffeine even if
its use was contraindicated by existing medical conditions,
and to consume these supplements in uncontrolled
amounts. A viable alternative to unrestricted use would be
the regulated use of ephedra and caffeine by prescription
with proper physician monitoring, which in our opinion
remains a viable option to debate.
Table 1 Summary of meta-analysis of weight loss drugs
Agent Duration
(months)
Number of
studies
Mean weight loss
(kg) from meta-
analysis
95% CI range
(kg)
Sibutramine 12 5 4.45 3.6 to 5.3
Orlistat 12 22 2.89 2.3 to 3.5
Phentermine 6 6 3.60 0.6 to 6.0
Bupropion 12 3 2.77 1.1 to 4.5
Abbreviation: CI, confidence interval.
Adapted from Li et al.9
International Journal of Obesity (2007) 31, 1482–1483
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Lastly, we disagree with Inchiosa’s assertion that ‘it would
appear difficult to conclude that this prescription represents
a useful option for the treatment of obesity.’ Table 1
summarizes a recent meta-analysis of the currently approved
medications used for the treatment of obesity and the range
of weight loss associated with each.9 Many of these studies
included a low-calorie diet in addition to the medication. In
our 9-month study, participants were asked not to alter their
normal dietary patterns or to change their physical activity
levels. The mean weight loss in the treatment group (7.61 kg;
95% confidence interval: 5.3–9.7 kg) is greater than the
means noted for any of the drugs. While it is inappropriate
to compare a single study to a larger number of studies
investigating the effects of pharmaceutical agents, our results
suggest that further studies of dietary supplements contain-
ing ephedra and caffeine are warranted. Rather than dismiss
a modest level of ephedra and caffeine, combined with
vitamins, minerals and omega-3 fatty acids, as not useful for
the treatment of obesity, additional studies are needed to
determine if such an approach, prescribed and monitored by
a physician, can safely and effectively be employed as one
aspect of addressing the current obesity epidemic.
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